by Walter Gunzburg | May 21, 2026 | News
LAS VEGAS, May 20, 2026 /PRNewswire/ — Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today...
by Walter Gunzburg | Apr 23, 2026 | News
“SG Austria/Austrianova appoints biotech investor C. Thomas Paschall to its Board following a successful 2025 funding round, strengthening global growth, partnerships, and strategic expansion initiatives.” SINGAPORE – April 21, 2026 – SG...
by Walter Gunzburg | Nov 19, 2025 | News, Press Release
LAS VEGAS, NEVADA, November 18, 2025 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced that its 50/50 joint venture...
by Walter Gunzburg | Sep 19, 2025 | News, Press Release
LAS VEGAS, Sept. 18, 2025 /PRNewswire/ — Avant Technologies Inc. (OTCQB: AVAI) (“Avant” or the “Company”), a Nevada-based corporation, and Austrianova (SGAustria Pte. Ltd.), a Singapore-based biotechnology leader, today announced the...
by Walter Gunzburg | Nov 1, 2023 | News, Press Release
Austrianova announces German subsidiary and new location in Singapore SG Austria (“Austrianova”), a leading provider of cell encapsulation, has established a German subsidiary in Munich and moved to a new location in Singapore. SINGAPORE, October 31, 2023...
by Walter Gunzburg | Jun 26, 2023 | News
FIGURE 6. Secretion of IgG from encapsulated clone 6B1 cells. (A). Representative image of capsule four in bright field and fluorescence showing homogenous eGFP expression in encapsulated cells. Encapsulation of clone 6B1 cells. Cells were encapsulated in...
